Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
LONDON -(Dow Jones)- AstraZeneca PLC (AZN) and Bristol-Myers Squibb Co.'s ( BMY) established diabetes drug Onglyza has been approved in Europe as a combination therapy with insulin to improve blood sugar control in adult patients with Type 2 diabetes.
The European Commission's green light was based on late-stage 24-week data that showed Onglyza, when added to insulin, reduced blood sugar levels significantly in adult patients with Type 2 diabetes compared with placebo added to insulin, the companies said in a statement Monday.
http://www.nasdaq.com/aspx/stock-ma...bms-diabetes-drug-for-diabetes-2-with-insulin
The European Commission's green light was based on late-stage 24-week data that showed Onglyza, when added to insulin, reduced blood sugar levels significantly in adult patients with Type 2 diabetes compared with placebo added to insulin, the companies said in a statement Monday.
http://www.nasdaq.com/aspx/stock-ma...bms-diabetes-drug-for-diabetes-2-with-insulin
